BIODESIX, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BIODESIX, INC. (BDSX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $820.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- BIODESIX, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $820.00K, a 21.08% decline year-over-year.
- BIODESIX, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.11M, a 14.71% increase year-over-year.
- BIODESIX, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.05M, a 30.50% decline year-over-year.
- BIODESIX, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.04M, a 14.70% decline year-over-year.
- BIODESIX, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $4.14M, a 37.65% decline from fiscal 2024.
- BIODESIX, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.64M, a 23.54% increase from fiscal 2023.
- BIODESIX, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $5.37M, a 9.86% decline from fiscal 2022.
- BIODESIX, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $5.96M, a 20.57% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $820.00K 10-Q · filed 2026-08-05 | $1.94M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $1.11M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $4.14M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $1.05M 10-Q · filed 2025-11-03 | $2.09M derived: sum of 2 quarters · filed 2026-08-05 | $3.06M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $1.04M 10-Q · filed 2026-08-05 | $2.01M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $972.00K 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $6.64M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $1.51M 10-Q · filed 2025-11-03 | $2.73M derived: sum of 2 quarters · filed 2025-11-03 | $5.37M derived: sum of 3 quarters · filed 2025-11-03 | |
| 2024-06-30 | $1.22M 10-Q · filed 2025-11-03 | $3.86M derived: sum of 2 quarters · filed 2025-11-03 | ||
| 2024-03-31 | $2.64M 10-Q · filed 2025-11-03 | |||
| 2023-12-31 | $5.37M 10-K · filed 2025-03-03 | |||
| 2023-09-30 | $954.00K 10-Q · filed 2024-11-01 | $2.01M derived: sum of 2 quarters · filed 2024-11-01 | $4.29M derived: sum of 3 quarters · filed 2024-11-01 | |
| 2023-06-30 | $1.06M 10-Q · filed 2024-11-01 | $3.34M derived: sum of 2 quarters · filed 2024-11-01 | ||
| 2023-03-31 | $2.28M 10-Q · filed 2024-11-01 | |||
| 2022-12-31 | $5.96M 10-K · filed 2024-03-01 | |||
| 2022-09-30 | $1.17M 10-Q · filed 2023-11-07 | $2.54M derived: sum of 2 quarters · filed 2023-11-07 | $3.88M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $1.37M 10-Q · filed 2023-11-07 | $2.71M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $1.35M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $4.94M 10-K · filed 2023-03-06 | |||
| 2021-09-30 | $1.39M 10-Q · filed 2022-11-03 | $1.93M derived: sum of 2 quarters · filed 2022-11-03 | $3.68M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $539.00K 10-Q · filed 2022-11-03 | $539.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $1.75M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $3.71M 10-K · filed 2022-03-14 | |||
| 2020-09-30 | $100.00K 10-Q · filed 2021-11-15 | $155.00K derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-06-30 | $55.00K 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $170.00K 10-K · filed 2021-03-16 | |||
| 2019-09-30 | $45.00K 10-Q · filed 2020-12-10 | $94.00K derived: sum of 2 quarters · filed 2020-12-10 | $125.00K derived: sum of 3 quarters · filed 2020-12-10 | |
| 2019-06-30 | $49.00K 10-Q · filed 2020-12-10 | $80.00K derived: sum of 2 quarters · filed 2020-12-10 | ||
| 2019-03-31 | $31.00K 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |